Integra LifeSciences [IART] vs Enovis [ENOV] Detailed Stock Comparison
Integra LifeSciences
NASDAQ
Loading...
Enovis
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Integra LifeSciences wins in 9 metrics, Enovis wins in 10 metrics, with 0 ties. Enovis appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Integra LifeSciences | Enovis | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 66.48 | -2.12 | Enovis |
| Price-to-Book Ratio | 1.13 | 0.70 | Enovis |
| Debt-to-Equity Ratio | 194.07 | 56.75 | Enovis |
| PEG Ratio | 5.98 | -0.02 | Enovis |
| EV/EBITDA | 9.60 | 8.90 | Enovis |
| Profit Margin (TTM) | -30.87% | -37.80% | Integra LifeSciences |
| Operating Margin (TTM) | 7.86% | 2.41% | Integra LifeSciences |
| EBITDA Margin (TTM) | 7.86% | 2.41% | Integra LifeSciences |
| Return on Equity | -38.92% | -28.25% | Enovis |
| Return on Assets (TTM) | 2.43% | 0.89% | Integra LifeSciences |
| Free Cash Flow (TTM) | $15.01M | $-67.21M | Integra LifeSciences |
| 1-Year Return | -13.80% | -26.81% | Integra LifeSciences |
| Price-to-Sales Ratio (TTM) | 0.72 | 0.82 | Integra LifeSciences |
| Enterprise Value | $2.94B | $3.23B | Enovis |
| EV/Revenue Ratio | 1.81 | 1.48 | Enovis |
| Gross Profit Margin (TTM) | 50.37% | 59.29% | Enovis |
| Revenue per Share (TTM) | $21 | $39 | Enovis |
| Earnings per Share (Diluted) | $-6.54 | $-14.95 | Integra LifeSciences |
| Beta (Stock Volatility) | 1.20 | 1.79 | Integra LifeSciences |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Integra LifeSciences vs Enovis Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Integra LifeSciences | -2.65% | -5.82% | 9.37% | 18.68% | -32.28% | -34.58% |
| Enovis | 0.44% | -1.28% | 10.33% | -1.77% | -12.81% | -28.40% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Integra LifeSciences | -13.80% | -66.94% | -67.70% | -53.11% | -22.41% | -17.25% |
| Enovis | -26.81% | -38.16% | -44.90% | -46.26% | 32.61% | -10.09% |
News Based Sentiment: Integra LifeSciences vs Enovis
Integra LifeSciences
News based Sentiment: MIXED
The month presented a mixed bag for Integra LifeSciences, with a stock price decline and negative price prediction offset by a clear growth strategy for 2026 and ongoing operational improvements. Analyst sentiment remains cautious, reflecting the ongoing challenges and uncertainties surrounding the company's turnaround.
Enovis
News based Sentiment: MIXED
September presented a mixed bag for Enovis, with strong earnings and positive analyst sentiment countered by institutional selling and emerging technical bearish signals. The company's strategic initiatives and revised guidance offer a positive outlook, but investors should remain cautious due to the conflicting signals and potential headwinds.
Performance & Financial Health Analysis: Integra LifeSciences vs Enovis
| Metric | IART | ENOV |
|---|---|---|
| Market Information | ||
| Market Cap | $1.17B | $1.81B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 1,202,480 | 929,710 |
| 90 Day Avg. Volume | 1,384,253 | 1,083,047 |
| Last Close | $15.06 | $31.72 |
| 52 Week Range | $11.06 - $27.13 | $25.47 - $49.83 |
| % from 52W High | -44.49% | -36.34% |
| All-Time High | $77.40 (Apr 26, 2021) | $129.72 (Jun 09, 2014) |
| % from All-Time High | -80.54% | -75.55% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.01% | 0.08% |
| Quarterly Earnings Growth | -0.01% | 0.08% |
| Financial Health | ||
| Profit Margin (TTM) | -0.31% | -0.38% |
| Operating Margin (TTM) | 0.08% | 0.02% |
| Return on Equity (TTM) | -0.39% | -0.28% |
| Debt to Equity (MRQ) | 194.07 | 56.75 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $13.33 | $45.11 |
| Cash per Share (MRQ) | $3.26 | $0.77 |
| Operating Cash Flow (TTM) | $70.89M | $188.06M |
| Levered Free Cash Flow (TTM) | $45.35M | $65.68M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | $0.00 |
Valuation & Enterprise Metrics Analysis: Integra LifeSciences vs Enovis
| Metric | IART | ENOV |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 66.48 | -2.12 |
| Forward P/E | 5.98 | 9.99 |
| PEG Ratio | 5.98 | -0.02 |
| Price to Sales (TTM) | 0.72 | 0.82 |
| Price to Book (MRQ) | 1.13 | 0.70 |
| Market Capitalization | ||
| Market Capitalization | $1.17B | $1.81B |
| Enterprise Value | $2.94B | $3.23B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.81 | 1.48 |
| Enterprise to EBITDA | 9.60 | 8.90 |
| Risk & Other Metrics | ||
| Beta | 1.20 | 1.79 |
| Book Value per Share (MRQ) | $13.33 | $45.11 |
Financial Statements Comparison: Integra LifeSciences vs Enovis
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | IART | ENOV |
|---|---|---|
| Revenue/Sales | $415.61M | $558.83M |
| Cost of Goods Sold | $206.27M | $226.61M |
| Gross Profit | $209.33M | $332.23M |
| Research & Development | $27.00M | $28.53M |
| Operating Income (EBIT) | $-1.31M | $-42.91M |
| EBITDA | $39.15M | $27.14M |
| Pre-Tax Income | $-530.95M | $-57.35M |
| Income Tax | $-46.88M | $-1.77M |
| Net Income (Profit) | $-484.07M | $-55.71M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | IART | ENOV |
|---|---|---|
| Cash & Equivalents | $239.10M | $38.46M |
| Total Current Assets | $1.11B | $1.22B |
| Total Current Liabilities | $918.45M | $477.42M |
| Long-Term Debt | $1.39B | $1.42B |
| Total Shareholders Equity | $1.52B | $2.62B |
| Retained Earnings | $914.62M | $-338.99M |
| Property, Plant & Equipment | $561.38M | $492.24M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | IART | ENOV |
|---|---|---|
| Operating Cash Flow | $5.80M | $-1.07M |
| Capital Expenditures | $-28.92M | $-43.26M |
| Free Cash Flow | $-40.18M | $-44.86M |
| Debt Repayment | $-15.24M | $-15.44M |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | IART | ENOV |
|---|---|---|
| Shares Short | 7.19M | 6.90M |
| Short Ratio | 4.79 | 5.90 |
| Short % of Float | 0.15% | 0.18% |
| Average Daily Volume (10 Day) | 1,202,480 | 929,710 |
| Average Daily Volume (90 Day) | 1,384,253 | 1,083,047 |
| Shares Outstanding | 77.16M | 55.88M |
| Float Shares | 59.27M | 56.43M |
| % Held by Insiders | 0.14% | 0.02% |
| % Held by Institutions | 0.95% | 1.21% |
Dividend Analysis & Yield Comparison: Integra LifeSciences vs Enovis
| Metric | IART | ENOV |
|---|---|---|
| Last 12-Month Dividend | N/A | $0.00 |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | $0.00 |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | $0.00 |
| Ex-Dividend Date | N/A | N/A |